ATE302759T1 - Prostaglandin endoperoxyde h synthase biosynthese inhibitoren - Google Patents

Prostaglandin endoperoxyde h synthase biosynthese inhibitoren

Info

Publication number
ATE302759T1
ATE302759T1 AT99953259T AT99953259T ATE302759T1 AT E302759 T1 ATE302759 T1 AT E302759T1 AT 99953259 T AT99953259 T AT 99953259T AT 99953259 T AT99953259 T AT 99953259T AT E302759 T1 ATE302759 T1 AT E302759T1
Authority
AT
Austria
Prior art keywords
cox
cyclooxygenase
endoperoxyde
prostaglandin
biosynthesis inhibitors
Prior art date
Application number
AT99953259T
Other languages
English (en)
Inventor
Lawrence A Black
Anwer Basha
Teodozyj Kolasa
Michael E Kort
Huaqing Liu
Catherine M Mccarty
Meena V Patel
Jeffrey J Rohde
Michael J Coghlan
Andrew O Stewart
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Priority claimed from US09/427,768 external-priority patent/US6307047B1/en
Application granted granted Critical
Publication of ATE302759T1 publication Critical patent/ATE302759T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT99953259T 1998-10-27 1999-10-27 Prostaglandin endoperoxyde h synthase biosynthese inhibitoren ATE302759T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17960598A 1998-10-27 1998-10-27
US26187299A 1999-03-03 1999-03-03
US29849099A 1999-04-23 1999-04-23
PCT/US1999/025234 WO2000024719A1 (en) 1998-10-27 1999-10-27 Prostaglandin endoperoxide h synthase biosynthesis inhibitors
US09/427,768 US6307047B1 (en) 1997-08-22 1999-10-27 Prostaglandin endoperoxide H synthase biosynthesis inhibitors

Publications (1)

Publication Number Publication Date
ATE302759T1 true ATE302759T1 (de) 2005-09-15

Family

ID=27497355

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99953259T ATE302759T1 (de) 1998-10-27 1999-10-27 Prostaglandin endoperoxyde h synthase biosynthese inhibitoren

Country Status (19)

Country Link
EP (1) EP1124804B1 (de)
JP (1) JP2003512292A (de)
KR (1) KR100666838B1 (de)
CN (1) CN1279026C (de)
AT (1) ATE302759T1 (de)
BG (1) BG65261B1 (de)
BR (1) BR9914858A (de)
CA (1) CA2347982A1 (de)
CZ (1) CZ300570B6 (de)
DE (1) DE69926903T2 (de)
DK (1) DK1124804T3 (de)
ES (1) ES2249919T3 (de)
HK (1) HK1041876B (de)
HU (1) HUP0105248A3 (de)
NO (1) NO318623B1 (de)
PL (1) PL198503B1 (de)
SK (1) SK286806B6 (de)
TR (1) TR200101765T2 (de)
WO (1) WO2000024719A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9813998A (pt) 1997-11-19 2000-09-26 Kowa Co Novos derivados de piridazina e produtos medicinais contendo os mesmos como ingredientes efetivos
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
JP2000247959A (ja) 1999-02-26 2000-09-12 Kowa Co ピリダジン−３−オン誘導体及びこれを含有する医薬
CO5261556A1 (es) 1999-12-08 2003-03-31 Pharmacia Corp Composiciones inhibidoras de ciclooxigenasa-2 que tiene rapido acceso de efecto terapeutico
US6664256B1 (en) 2000-07-10 2003-12-16 Kowa Co., Ltd. Phenylpyridazine compounds and medicines containing the same
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
AR031129A1 (es) 2000-09-15 2003-09-10 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
MY131964A (en) 2000-09-15 2007-09-28 Pharmacia Corp 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
US7012098B2 (en) 2001-03-23 2006-03-14 Pharmacia Corporation Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
DE10129320A1 (de) 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
AP1822A (en) 2002-02-14 2008-01-30 Pharmacia Corp Substituted pyridinones as modulators of P38 MAP kinase.
PT1572173E (pt) 2002-12-13 2010-05-10 Warner Lambert Co Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
ES2211344B1 (es) * 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
BRPI0408359A (pt) 2003-03-18 2006-03-21 Kowa Co derivados de fenilpiridazina solúveis em água e medicamentos contendo os mesmos
PT1534305E (pt) 2003-05-07 2007-02-28 Osteologix As Tratamento de afecções cartilagineas / osseas com sais de estroncio hidrosoluveis
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
US7728031B2 (en) 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
EP1916240A1 (de) * 2006-10-25 2008-04-30 Syngeta Participations AG Neue Pyridazin-Derivate
CN102058885B (zh) 2006-12-22 2013-04-10 瑞蔻达蒂爱尔兰有限公司 采用α2δ配体和NSAID的下泌尿道疾病的联合治疗
DE102007008839A1 (de) 2007-02-23 2008-08-28 Bayer Healthcare Ag Verfahren zur Herstellung von 4-(3-Hydroxy-3-methyl-butoxy)-5-[4-(methylsulfonyl)phenyl]-2-arylpyridazin-3(2H)-onen
DE102007008843A1 (de) 2007-02-23 2008-08-28 Bayer Healthcare Ag Verfahren zur Herstellung von 4,5-Dihalogen-2-aryl-2H-pyridazin-3-onen
DE102007008840A1 (de) 2007-02-23 2008-08-28 Bayer Healthcare Ag Neue polymorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-methyl-1-butoxy)-5-[4-methylsulfonyl)phenyl]-3(2H)-pyridazinon (FHMP)
DE102007020689A1 (de) * 2007-05-03 2008-11-06 Bayer Healthcare Ag Neue polymorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-methyl-1-butoxy-5-[4-methylsulfonyl)phenyl]3/2H)-pyridazinon (FHMP)
DE102007020690A1 (de) * 2007-05-03 2008-11-06 Bayer Healthcare Ag Neue amorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-mehtyl-1-butoxy)-6[4-methylsulfonyl)phenyl]-3(2H)-pyridazinon (FHMP)
DE102007025717A1 (de) * 2007-06-01 2008-12-11 Merck Patent Gmbh Arylether-pyridazinonderivate
GB0716414D0 (en) * 2007-08-22 2007-10-03 Syngenta Participations Ag Novel insecticides
CN101809021B (zh) 2007-09-11 2013-04-24 雅培制药有限公司 八氢-吡咯并[3,4-b]吡咯n-氧化物
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
JP2012131708A (ja) * 2009-04-28 2012-07-12 Nissan Chem Ind Ltd ４位置換ピリダジノン化合物及びｐ２ｘ７受容体阻害剤
FR2969606B1 (fr) * 2010-12-22 2013-01-11 Pf Medicament Derives de diarylpyridazinones, leur preparation et leur application en therapeutique humaine
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
WO2018049027A1 (en) 2016-09-07 2018-03-15 Trustees Of Tufts College Combination therapies using immuno-dash inhibitors and pge2 antagonists
CN107334767B (zh) * 2017-06-08 2019-03-05 中国医学科学院医药生物技术研究所 一种哒嗪酮类化合物在肿瘤治疗中的应用
WO2021124344A1 (en) * 2019-12-18 2021-06-24 Abida Pyridazine derivatives and their use as cyclooxygenase-2 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4238490A (en) * 1979-02-12 1980-12-09 Diamond Shamrock Corporation Antihypertensive pyridazin(2H)-3-ones
BR8108745A (pt) * 1980-08-07 1982-07-06 Diamond Shamrock Corp Difenilpiridazinonas herbicidas e reguladores do crescimento da planta
US5622948A (en) * 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents
US6342510B1 (en) * 1995-06-12 2002-01-29 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist
EP0975604B1 (de) * 1997-03-14 2004-07-21 Merck Frosst Canada & Co. Pyridazinone als inhibitoren von cyclooxygenase-2
JP2002511887A (ja) * 1997-08-22 2002-04-16 アボツト・ラボラトリーズ プロスタグランジンエンドペルオキシドｈシンターゼ生合成阻害薬
JP2003516925A (ja) * 1997-08-22 2003-05-20 アボット・ラボラトリーズ プロスタグランジンエンドペルオキシドｈシンターゼ生合成阻害剤としてのアリールピリダジノン
EP1007515A1 (de) * 1997-08-22 2000-06-14 Abbott Laboratories Arylpyridazinone als hemmer der biosynthese der prostaglandin-endoperoxid-h-synthase

Also Published As

Publication number Publication date
CA2347982A1 (en) 2000-05-04
HK1041876A1 (en) 2002-07-26
NO20012061L (no) 2001-06-27
TR200101765T2 (tr) 2002-02-21
HK1041876B (en) 2006-06-23
CN1342149A (zh) 2002-03-27
PL349256A1 (en) 2002-07-01
NO318623B1 (no) 2005-04-18
CZ300570B6 (cs) 2009-06-17
BR9914858A (pt) 2002-02-05
CN1279026C (zh) 2006-10-11
KR100666838B1 (ko) 2007-01-11
EP1124804B1 (de) 2005-08-24
SK286806B6 (sk) 2009-05-07
KR20010081101A (ko) 2001-08-27
JP2003512292A (ja) 2003-04-02
HUP0105248A2 (hu) 2002-07-29
EP1124804A1 (de) 2001-08-22
HUP0105248A3 (en) 2002-09-30
BG105523A (en) 2001-12-29
PL198503B1 (pl) 2008-06-30
WO2000024719A1 (en) 2000-05-04
NO20012061D0 (no) 2001-04-26
DK1124804T3 (da) 2005-12-12
CZ20011481A3 (cs) 2001-09-12
BG65261B1 (bg) 2007-10-31
ES2249919T3 (es) 2006-04-01
DE69926903D1 (en) 2005-09-29
SK5542001A3 (en) 2001-12-03
DE69926903T2 (de) 2006-07-13

Similar Documents

Publication Publication Date Title
DE69926903D1 (en) Prostaglandin endoperoxyde h synthase biosynthese inhibitoren
CA2299300A1 (en) Arylpyridazinones as prostaglandin endoperoxide h synthase bisoynthesis inhibitors
ATE319691T1 (de) Prostaglandin endoperoxyde h synthase biosynthese inhibitoren
Reddy et al. C-Phycocyanin, a selective cyclooxygenase-2 inhibitor, induces apoptosis in lipopolysaccharide-stimulated RAW 264.7 macrophages
Gedawy et al. Design, synthesis and biological evaluation of novel pyrazole sulfonamide derivatives as dual COX-2/5-LOX inhibitors
Chan et al. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5 H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles
Esser et al. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2
Pairet et al. Experimental models used to investigate the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2 by non-steroidal anti-inflammatory drugs
Feldman et al. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?
Frölich A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes
Maiden Capsule endoscopic diagnosis of nonsteroidal antiinflammatory drug-induced enteropathy
Lolli et al. A new class of ibuprofen derivatives with reduced gastrotoxicity
BRPI0011172B8 (pt) derivados do 4,5-diaril-3(2h)-furanona como inibidores de ciclooxigenase-2
Singh Bahia et al. Inhibitors of microsomal prostaglandin E2 synthase‐1 enzyme as emerging anti‐inflammatory candidates
EP1391201A4 (de) Medizinische zusammensetzungen
Ramalho et al. The search for new COX-2 inhibitors: a review of 2002–2008 patents
Petrovic et al. Using N, N, N’, N’-tetramethyl-p-phenylenediamine (TMPD) to assay cyclooxygenase activity in vitro
Rasooli et al. Synergistic effects of deuterium depleted water and Mentha longifolia L. essential oils on sepsis-induced liver injuries through regulation of cyclooxygenase-2
Naureen et al. Discovery of indole-based tetraarylimidazoles as potent inhibitors of urease with low antilipoxygenase activity
Anuar et al. Nitric oxide‐releasing flurbiprofen reduces formation of proinflammatory hydrogen sulfide in lipopolysaccharide‐treated rat
Aprioku et al. Renal effects of non-steroidal anti inflammatory drugs in albino rats
Bastaki et al. Effect of Aspirin and ibuprofen either alone or in combination on gastric mucosa and bleeding time and on serum prostaglandin E2 and thromboxane A2 levels in the anaesthetized rats in vivo
Varandas et al. Design, synthesis and pharmacological evaluation of new nonsteroidal antiinflammatory 1, 3, 4-thiadiazole derivatives
Zhu et al. Cardioprotective effects of nitroparacetamol and paracetamol in acute phase of myocardial infarction in experimental rats
TR200000478T2 (tr) Prostaglandin endoperoksit H sentaz biyosentezi inhibitörleri olarak arilpiridazinonlar.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1124804

Country of ref document: EP

REN Ceased due to non-payment of the annual fee